Genmab and JARI Pharmaceuticals BV to Collaborate on Research And Development of Antibody Therapeutic Products
COPENHAGEN, Denmark, July 12 /PRNewswire-FirstCall/ -- Genmab A/S (CSE: GEN and Neuer Markt: GE9D) and JARI Pharmaceuticals BV, a privately held Dutch company, announced today an alliance to develop new antibody therapeutic products. Under the partnership JARI will provide novel commercially promising disease targets and Genmab will utilize its fully human antibody technology to create and develop new products.
The alliance will cover a range of disease areas within the inflammation area. The collaboration brings together Genmab's broad antibody development capabilities and extensive array of pre-clinical tools to generate and characterise fully human antibodies and JARI's skills in finding novel targets related to inflammatory diseases. Genmab and JARI will collaborate on the research, development and any eventual commercialization of the new antibody products and will share equally the development costs and revenues generated from out-licensing or sales of these products.
"Genmab is strongly pursuing its strategy of creating a broad based product portfolio as we announce this, our fifth partnership for disease targets this year." said Lisa N Drakeman Ph.D, Genmab's Chief Executive Officer. "We are happy to add JARI Pharmaceuticals to our growing list of partners which will enable us to bring urgently needed antibody treatments to patients"
"JARI is delighted to collaborate with Genmab, a company recognised internationally as a leader in its field", said Jaap Kampinga MD, CEO of JARI Pharmaceuticals BV. "This collaboration supports JARI's strategy to combine strengths in developing innovative therapeutics for inflammatory diseases utilising our LANTIS drug discovery programme for finding promising drug leads from unique natural sources."
About Genmab A/S
Genmab A/S is a biotechnology company that creates and develops fully human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, rheumatoid arthritis and other inflammatory conditions, and intends to assemble a broad portfolio of new therapeutic products arising from research into the human genome. At present, Genmab's commercial opportunities are based upon research conducted at leading international companies, including Roche, Immunex Corporation, Oxford GlycoSciences Ltd., Medarex, Inc., deCODE Genetics, Scancell, Ltd., Sequenom, Inc., Eos Biotechnology Inc., Glaucus Proteomics B.V., Bionomics, Paradigm Therapeutics and ACE BioSciences, as well as in its own laboratories. A broad alliance provides Genmab with access to Medarex Inc.'s array of proprietary technologies, including the UltiMAb(TM) platform for the rapid creation and development of fully human antibodies to virtually any disease target. Genmab is headquartered in Denmark and has operations in Utrecht, The Netherlands and Princeton, New Jersey in the US. For more information about Genmab, visit genmab.com .
About JARI Pharmaceuticals BV
JARI Pharmaceuticals BV is a biopharmaceutical company focused on discovery and development of drugs against infectious and non-infectious inflammatory diseases. JARI obtains candidate drugs from its own discovery platforms and by in-licensing. The discovery programme for non-infectious inflammatory diseases is based on the premise that various organisms present in humans have developed an ability to evade or modulate host defence mechanisms. JARI has the technology and expertise to identify and characterise the molecules responsible for conferring such properties using its LANTIS technology and to explore their therapeutic potential in relevant biological models. Over 50 acute and chronic clinical conditions can be traced to an underlying inflammatory disorder and together these comprise a major segment of the market for human pharmaceutical products. JARI's C5a receptor blocking compound JPD-003 has recently started Phase I clinical trials. For more information about JARI, visit jari.nl . |
